Amgen to present new data from cardiovascular portfolio, including late-breaking results from phase 3 VESALIUS-CV trial of Repatha at AHA scientific sessions: Thousand Oaks, Calif ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback